Literature DB >> 7893945

Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors.

A G Beck-Sickinger1, G Jung.   

Abstract

Secondary structure investigations, affinities, and activities of neuropeptide Y analogues with respect to the Y1 and the Y2 receptor are reviewed. The results are discussed with respect to the different prerequisites for affinities to both receptor subtypes. The results from a systematic scanning of the hormone using L-alanine and from a large variety of discontinuous and cyclic analogs suggest that two different conformations of neuropeptide Y are adopted at the Y1 and Y2 receptors. Whereas a C-terminal turn structure is suggested for Y1 receptor affinity, an alpha-helical conformation of the C-terminus is afforded for good binding to the Y2 receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7893945     DOI: 10.1002/bip.360370207

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  14 in total

1.  Substitution of D-Trp32 in NPY destabilizes the binding transition state to the Y1 receptor site in SK-N-MC cell membranes.

Authors:  R Zand; C L Marcelo; R MacKenzie; L Georgic; D Maclean; W R Dunham
Journal:  Neurochem Res       Date:  1997-04       Impact factor: 3.996

2.  Neuropeptide Y bioavailability is suppressed in the hindlimb of female Sprague-Dawley rats.

Authors:  Dwayne N Jackson; Kevin J Milne; Earl G Noble; J Kevin Shoemaker
Journal:  J Physiol       Date:  2005-08-04       Impact factor: 5.182

3.  Design and Synthesis of Peptide YY Analogues with C-terminal Backbone Amide-to-Ester Modifications.

Authors:  Louise Albertsen; Julie J Andersen; Johan F Paulsson; Jens K Thomsen; Jens C Norrild; Kristian Strømgaard
Journal:  ACS Med Chem Lett       Date:  2013-10-21       Impact factor: 4.345

4.  Structure activity studies of mast cell activation and hypotension induced by neuropeptide Y (NPY), centrally truncated and C-terminal NPY analogues.

Authors:  L J Cross; A G Beck-Sickinger; M Bienert; W Gaida; G Jung; E Krause; M Ennis
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

5.  The interaction of neuropeptide Y with negatively charged and zwitterionic phospholipid membranes.

Authors:  Lars Thomas; Holger A Scheidt; Andrea Bettio; Annette G Beck-Sickinger; Daniel Huster; Olaf Zschörnig
Journal:  Eur Biophys J       Date:  2009-03-25       Impact factor: 1.733

6.  High-affinity neuropeptide Y receptor antagonists.

Authors:  A J Daniels; J E Matthews; R J Slepetis; M Jansen; O H Viveros; A Tadepalli; W Harrington; D Heyer; A Landavazo; J J Leban; A Spaltenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

7.  The anorexic hormone Peptide YY3-36 is rapidly metabolized to inactive Peptide YY3-34 in vivo.

Authors:  Signe Toräng; Simon Veedfald; Mette Marie Rosenkilde; Bolette Hartmann; Jens Juul Holst
Journal:  Physiol Rep       Date:  2015-07

Review 8.  NPY and Gene Therapy for Epilepsy: How, When,... and Y.

Authors:  Stefano Cattaneo; Gianluca Verlengia; Pietro Marino; Michele Simonato; Barbara Bettegazzi
Journal:  Front Mol Neurosci       Date:  2021-01-22       Impact factor: 5.639

9.  Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice.

Authors:  Henrik H Hansen; Rikke V Grønlund; Tamara Baader-Pagler; Peter Haebel; Harald Tammen; Leif Kongskov Larsen; Jacob Jelsing; Niels Vrang; Thomas Klein
Journal:  Sci Rep       Date:  2021-04-13       Impact factor: 4.379

10.  Neuropeptide Y receptors: how to get subtype selectivity.

Authors:  Xavier Pedragosa-Badia; Jan Stichel; Annette G Beck-Sickinger
Journal:  Front Endocrinol (Lausanne)       Date:  2013-02-04       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.